<?xml version="1.0" encoding="UTF-8"?>
<p>Idelalisib and other approved PI3K inhibitors cause hyper-activation of the immune system resulting in significant autoimmune adverse events, including pneumonitis, and increase the risk of opportunistic infections, particularly when given as front-line therapy or in combination with anti-CD20 monoclonal antibodies.
 <sup>
  <xref rid="R92" ref-type="bibr">92</xref>,
  <xref rid="R93" ref-type="bibr">93</xref>
 </sup> In addition, in the relapsed setting, idelalisib plus rituximab treated patients have a shorter progression free survival and a higher drug discontinuation rate due to adverse events compared to acalabrutinib treated patients.
 <sup>
  <xref rid="R59" ref-type="bibr">59</xref>
 </sup>
</p>
